<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390975</url>
  </required_header>
  <id_info>
    <org_study_id>CHTF919GUS62</org_study_id>
    <nct_id>NCT00390975</nct_id>
  </id_info>
  <brief_title>Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis</brief_title>
  <official_title>An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis
      treated with tegaserod over 2 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    This study was terminated early as a result of regulatory action suspending tegaserod use in
    2007
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2007</completion_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients treated with tegaserod that improve gastric emptying at Week 2 as compared with baseline via a solid phase technetium gastric emptying time (GET)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in patients treated with tegaserod relative to: The proportion of patients that normalize gastric emptying</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of diabetic gastroparesis including postprandial fullness, early satiety, bloating, nausea and vomiting, and abdominal discomfort</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume and symptomatic response to a gastric satiety drink test (GSDT)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrogastrography (EGG)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The safety and tolerability of tegaserod</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastroparesis</condition>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegaserod</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females and males 18 to 75 years of age

          -  History of type I or type II diabetes mellitus for more than 3 years

          -  History of upper gastrointestinal symptoms consistent with diabetic gastroparesis

          -  Hemoglobin A1c &lt; 9.5%

          -  Delayed gastric emptying

        Exclusion Criteria:

          -  Abnormal endoscopy finding that can explain the presence of gastroparesis symptoms

          -  Medical conditions affecting gastric emptying

          -  A clinically significant medical condition that would interfere with the patient
             completing the trial

          -  Clinically significant abnormal creatinine level

          -  Known allergies to the same class of drug and/or allergies to eggs

          -  Severe obesity

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceutical Corporation</last_name>
    <role>Study Chair</role>
    <affiliation>NPC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40292</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2006</study_first_submitted>
  <study_first_submitted_qc>October 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 23, 2006</study_first_posted>
  <last_update_submitted>May 3, 2012</last_update_submitted>
  <last_update_submitted_qc>May 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2012</last_update_posted>
  <keyword>Tegaserod</keyword>
  <keyword>diabetes</keyword>
  <keyword>diabetic gastroparesis</keyword>
  <keyword>gastric emptying</keyword>
  <keyword>gastric retention</keyword>
  <keyword>electrogastrography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroparesis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegaserod</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

